2024

1. Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

   Arthritis Care and Research, Vol. 76, Núm. 11, pp. 1558-1565

2. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

   Arthritis and Rheumatology, Vol. 76, Núm. 4, pp. 587-598